Sensei Biotherapeutics Appoints New CMO and Director

Ticker: SNSE · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1829802

Sensei Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySensei Biotherapeutics, Inc. (SNSE)
Form Type8-K
Filed DateSep 20, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$360,000
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-appointment

TL;DR

Sensei Bio brings in new CMO and board member, signaling potential strategic shifts.

AI Summary

Sensei Biotherapeutics, Inc. announced on September 17, 2024, changes in its executive and director roles. Dr. John F. McDonald has been appointed as the new Chief Medical Officer, and Ms. Jennifer L. Jones has joined the Board of Directors. These appointments are part of the company's ongoing efforts to advance its pipeline of novel immunotherapies.

Why It Matters

The appointment of a new Chief Medical Officer and a Board member suggests a strategic shift or expansion in Sensei Biotherapeutics' leadership, potentially impacting its drug development and corporate strategy.

Risk Assessment

Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

  • Sensei Biotherapeutics, Inc. (company) — Registrant
  • Dr. John F. McDonald (person) — Appointed Chief Medical Officer
  • Ms. Jennifer L. Jones (person) — Appointed to Board of Directors
  • September 17, 2024 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. John F. McDonald has been appointed as the new Chief Medical Officer.

Who has joined the Board of Directors?

Ms. Jennifer L. Jones has joined the Board of Directors.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is September 17, 2024.

What is the principal executive office address for Sensei Biotherapeutics, Inc.?

The principal executive office address is 1405 Research Blvd, Suite 125, Rockville, MD 20850.

What is the company's telephone number?

The company's telephone number is (240) 243-8000.

Filing Stats: 1,034 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-09-20 16:31:04

Key Financial Figures

  • $360,000 — ement provides for (i) a base salary of $360,000, (ii) an annual bonus target equal to 3

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: September 20, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.